Preclinical evaluation of aluminum hydroxide-tethered interleukin-12 (JEN-101) therapy in pet dogs with advanced malignant melanoma - - GEO DataSets

Summary

Format

Summary
Summary (text)
Unique Identifier List

Send to:

Choose Destination

File
Clipboard
Collections

Links from BioProject

Preclinical evaluation of aluminum hydroxide-tethered interleukin-12 (JEN-101) therapy in pet dogs with advanced malignant melanoma

(Submitter supplied) A Phase I study was conducted to determine the tolerability, activity, and immune responses of JEN-101 in dogs with advanced melanoma. A 3+3 dose escalation design was used to evaluate intratumoral injection of JEN-101 at 1, 3, 10, or 20 μg/kg every three weeks for four cycles. A second course was allowable in the absence of disease progression or toxicity. Peripheral blood, serum, and tumor biopsies were collected at baseline and at pre-specified timepoints for pharmacokinetic and immune analyses, which included serum cytokines, immunohistochemistry, and gene expression assessment. more...

Organism:: Canis lupus familiaris

Type:: Expression profiling by array

Platform:: GPL32796
21 Samples

Download data: CSV

Series

Accession:: GSE278391

ID:: 200278391

Analyze with GEO2R

Supplemental Content

GEO DataSets

Functional Genomics Studies

Result Filters

Send to:

Links from BioProject

Supplemental Content

Related information

Important Links

Recent activity